Pavlos Msaouel

Jan 9, 2025 | nature.com | Pavlos Msaouel |Rahul Sheth |Amishi Y. Shah |Amado J. Zurita |Giannicola Genovese |Minghao Dang | +3 more

AbstractWe conducted a phase I trial to determine the optimal dose of triplet therapy with the tyrosine kinase inhibitor sitravatinib plus nivolumab plus ipilimumab in 22 previously untreated patients with advanced clear cell renal cell carcinoma. The primary endpoint was safety.

Sep 6, 2024 | digitalcommons.library.tmc.edu | Jose A. Karam |Pavlos Msaouel |Cara Haymaker |Surena F. Matin

Sitravatinib is an immunomodulatory tyrosine kinase inhibitor that can augment responses when combined with programmed death-1 inhibitors such as nivolumab. We report a single-arm, interventional, phase 2 study of neoadjuvant sitravatinib in combination with nivolumab in patients with locally advanced clear cell renal cell carcinoma (ccRCC) prior to curative nephrectomy (NCT03680521).

Jul 27, 2024 | cancernetwork.com | Pavlos Msaouel

Ubamatamab in combination with anti-PD-inhibition may enhance the immune response in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma, said Pavlos Msaouel, MD, PhD.

Jul 16, 2024 | nature.com | Andrew Hahn |Rebecca S. Tidwell |Amado J. Zurita |Sumit K. Subudhi |Pavlos Msaouel |Efstratios Koutroumpakis | +2 more

AbstractAndrogen signaling is central to prostate cancer and men’s health. Prior data indicates that increasing body fat is unfavorable in the localized setting yet associated with favorable outcomes in men with metastatic disease. Understanding the biological links between adiposity and prostate cancer may optimize the therapeutic index with ASI.

Apr 30, 2024 | hdsr.mitpress.mit.edu | Pavlos Msaouel

Column Editor’s Note: Randomized controlled trials (RCTs) are regarded as a form of ‘gold-standard’ for causal inferences in real-world settings. Real-world RCTs involve key design and analysis decisions that can strongly affect the meaning and validity of conclusions drawn. Dr. Msaouel explores some of these issues and questions from an information science perspective, shedding light on, among other aspects, random sampling and randomization, refutational information, and Bayesian shrinkage.